Nutex Health Terminates Material Definitive Agreement

TL;DR

**Nutex Health just terminated a material agreement on Feb 15, 2024; details are sparse but it could impact future operations.**

AI Summary

Nutex Health, Inc. filed an 8-K report on February 15, 2024, disclosing the termination of a material definitive agreement. The filing indicates this event occurred on the same date, February 15, 2024. Specific details regarding the nature of the agreement, the parties involved, or the reasons for its termination are not provided within this excerpt of the filing.

Why It Matters

The termination of a material definitive agreement can significantly impact Nutex Health's strategic direction, operational capabilities, or financial performance, depending on the nature of the agreement. Without further details, the full implications remain uncertain for investors.

Risk Assessment

Risk Level: medium — The termination of a material agreement introduces uncertainty regarding Nutex Health's future operations and financial outlook, as the specifics of the agreement and reasons for termination are not disclosed in this filing.

Key Players & Entities

• Nutex Health, Inc. (company) — registrant
• February 15, 2024 (date) — date of earliest event reported
• Delaware (location) — state of incorporation
• 001-41346 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value NUTX The NASDAQ Stock Mar
• $25.0 million — e Company may request advances of up to $25.0 million each from Yorkville (or such greater am
• $100 m — Pre-Paid Advance") for a total of up to $100 million, which will be purchased by Yorkv
• $25 m — initial Pre-Paid Advance requested was $25 million, $15 million of which was paid on
• $15 million — Paid Advance requested was $25 million, $15 million of which was paid on April 11, 2023, wi
• $10 million — d on April 11, 2023, with the remaining $10 million to be paid upon mutual agreement of the
• $8.0 million — ipal of the initial Pre-Paid Advance to $8.0 million. Additionally, the Company made Optiona
• $5.2 million — he Company made Optional Prepayments of $5.2 million in accordance with the PPA, consisting
• $4.9 million — accordance with the PPA, consisting of $4.9 million of principal and $0.3 million attribute
• $0.3 million — isting of $4.9 million of principal and $0.3 million attributed to the Payment Premium. The
• $3.1 million — aid Advance as of December 31, 2023 was $3.1 million. On January 30, 2024, the Company paid

Filing Documents

• nutx-20240215x8k.htm (8-K) — 29KB
• 0001558370-24-001249.txt ( ) — 154KB
• nutx-20240215.xsd (EX-101.SCH) — 4KB
• nutx-20240215_def.xml (EX-101.DEF) — 3KB
• nutx-20240215_lab.xml (EX-101.LAB) — 17KB
• nutx-20240215_pre.xml (EX-101.PRE) — 11KB
• nutx-20240215x8k_htm.xml (XML) — 5KB

02. Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement. On February 8, 2024, Nutex Health, Inc. (the "Company") and YA II PN, Ltd. ("Yorkville"), terminated the Pre-Paid Advance Agreement dated as of April 11, 2023, as amended (the "PPA") by the mutual consent of the parties, effective as of February 15, 2024. As previously disclosed, pursuant to the PPA, the Company may request advances of up to $25.0 million each from Yorkville (or such greater amount that parties may mutually agree) (each, a "Pre-Paid Advance") for a total of up to $100 million, which will be purchased by Yorkville at 90% of the face amount. The initial Pre-Paid Advance requested was $25 million, $15 million of which was paid on April 11, 2023, with the remaining $10 million to be paid upon mutual agreement of the parties. Since the receipt of the initial Pre-Paid Advance, 21.4 million shares of Common Stock have been issued to Yorkville, reducing the principal of the initial Pre-Paid Advance to $8.0 million. Additionally, the Company made Optional Prepayments of $5.2 million in accordance with the PPA, consisting of $4.9 million of principal and $0.3 million attributed to the Payment Premium. The principal of the initial Pre-Paid Advance as of December 31, 2023 was $3.1 million. On January 30, 2024, the Company paid off in full the remaining outstanding balance of the PPA. As of February 15, 2024, the Company's obligation to request the remaining $10 million Pre-Paid Advance, and Yorkville's obligation to purchase the remaining $10 million Pre-Paid Advance, has been terminated. At the time of termination, there were no outstanding Pre-Paid Advance, advance notices or shares of Common Stock to be issued under the PPA. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the PPA.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 15, 2024 Nutex Health Inc. By: /s/ Jon C. Bates Jon C. Bates Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR